DAE HWA Pharm

대화제약 · 067080

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$157.8M (₩217.8B)

Overview

DAE HWA Pharm makes prescription and over-the-counter medicines, finished pharmaceutical products used by patients and dispensed through hospitals, clinics, and pharmacies in South Korea.

It supplies its products to the domestic healthcare market and is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company is currently profitable, though its revenue has declined on a year-over-year basis.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$103.7M

▼ −4.2% YoY

Operating profit · FY2025

US$2.3M

▼ −52.9% YoY

Net income · FY2025

US$1.7M

▲ +180.8% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$102.4M(₩141.4B)	US$108.3M(₩149.4B)	US$103.7M(₩143.1B)
Operating profit	US$1.4M(₩2B)	US$4.9M(₩6.7B)	US$2.3M(₩3.2B)
Net income	−US$372.7K(−₩514.3M)	US$601.3K(₩829.8M)	US$1.7M(₩2.3B)

Revenue

FY2023US$102.4M
FY2024US$108.3M
FY2025US$103.7M

Operating profit

FY2023US$1.4M
FY2024US$4.9M
FY2025US$2.3M

Net income

FY2023−US$372.7K
FY2024US$601.3K
FY2025US$1.7M

Key ratios (FY2025)

ROE

2.9%

Debt/Eq

166.4%

Op. margin

2.2%

Net margin

1.6%

Rev. YoY

▼ −4.2%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?